Eledon Pharmaceuticals IncELDN
Price$2.44

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$98.6MTTM through 30 Jun 2026
Free Cash Flow -$73.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-42.2%ROE
-27.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio7.48x
Net Debt-$133.3Mnet cash position
Cash & Equivalents$6.8M

Quality Metrics

Altman Z-Score-4.04
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'15'16
FY2016: $0
Diluted EPS-$0.90TTM
'21'22'23'24'25
FY2025: $-0.56

Dividend

No dividend

Capital Allocation

R&D Spend$67.9M

Segment Performance

SegmentRevenueYoYOutlook
Immunology and Transplantation Therapies$00.0%
View details

Advancing towards Phase 3 development in kidney transplantation and initiating additional trials in islet cell and liver transplantation.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.